论文部分内容阅读
原发性肝癌是世界第五位最常见的恶性肿瘤,其发病率在欧美、日本等国居高不下,中国更是全世界肝癌发病率最高的国家。大部分确诊肝癌病例为晚期和不宜手术患者,且术后复发率较高,预后不佳。肝癌目前的辅助化疗药物敏感性较低,近年研究发现,新型免疫抑制剂雷帕霉素可以抑制肝细胞癌生长,遏制肝癌细胞转移、侵袭能力,还兼有同其他抗肝癌药物的协同作用,有望成为肝细胞癌治疗的新型分子靶向药物。特别是与其他传统化疗药物的协同作用现已成为国内外研究的热点。本文重点综述雷帕霉素抑制肝癌细胞增殖的研究现状与展望。
Primary liver cancer is the fifth most common malignant tumor in the world. Its incidence is high in Europe, the United States, Japan and other countries. China is also the country with the highest incidence of liver cancer in the world. Most confirmed cases of liver cancer in patients with advanced and should not be surgery, and postoperative recurrence rate is higher, the prognosis is poor. In recent years, the study found that the new immunosuppressive drug rapamycin can inhibit the growth of hepatocellular carcinoma, inhibit the metastasis and invasion ability of hepatoma cells, and also has the synergistic effect with other anti-hepatocarcinoma drugs, It is expected to become a new molecular targeted drug for the treatment of hepatocellular carcinoma. Especially with other traditional chemotherapeutic drugs synergy has become a hot spot at home and abroad. This article focuses on rapamycin inhibition of liver cancer cell proliferation research status and prospects.